MINT-ITRACONAZOLE CAPSULE

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

ITRACONAZOLE

제공처:

MINT PHARMACEUTICALS INC

ATC 코드:

J02AC02

INN (International Name):

ITRACONAZOLE

복용량:

100MG

약제 형태:

CAPSULE

구성:

ITRACONAZOLE 100MG

관리 경로:

ORAL

패키지 단위:

30

처방전 유형:

Prescription

치료 영역:

AZOLES

제품 요약:

Active ingredient group (AIG) number: 0123311002; AHFS:

승인 상태:

APPROVED

승인 날짜:

2017-03-22

제품 특성 요약

_Approved Product Monograph _
MINT-ITRACONAZOLE (itraconazole)
_ _
_Page 1 of 55_
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATIO N
PR
MINT-ITRACONAZOLE
Itraconazole Capsules
Capsule, 100 mg, Oral
Antimycotic for systemic use, triazole and tetrazole derivatives
Mint Pharmaceuticals Inc.
6575 Davand Drive,
Mississauga, Ontario,
L5T 2M3
Date of Initial Authorization:
March 22, 2017
Date of Revision:
May 17, 2023
Submission Control Number: 270537
_Approved Product Monograph _
MINT-ITRACONAZOLE (itraconazole)
_ _
_Page 2 of 55_
_ _
RECENT MAJOR LABEL CHANGES
2. CONTRAINDICATIONS
05/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.........................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................................
4
1
INDICATIONS
.................................................................................................................
4
1.1
Pediatrics
.........................................................................................................
4
1.2
Geriatrics
.........................................................................................................
4
2
CONTRAINDICATIONS
..................................................................................................
5
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
.........................................................
6
4
DOSAGE AND ADMINISTRATION
.................................................................................
7
4.1
Dosing Considerations
.....................................................................................
7
4.2
Recommended Dose and Dosage Adjustment
.................................................
7
4.4
Administration
......................................